Most Serious Side Effect Needing Urgent Care
Rhabdomyolysis, a breakdown of muscle tissue that can lead to kidney failure, requires immediate medical attention. Symptoms include muscle pain, weakness, dark urine, and fatigue.[1]
Why Rhabdomyolysis Stands Out
This rare but life-threatening effect occurs because lurbinectedin damages muscle cells, releasing proteins like myoglobin into the blood. It demands urgent evaluation to prevent organ damage, unlike more common effects like nausea or fatigue that providers monitor routinely.[1][2]
Other Side Effects That May Need Quick Attention
- Neutropenia or severe infection signs: Fever over 100.4°F (38°C), chills, or sore throat signal low white blood cells, risking sepsis. Seek care right away.[1]
- Infusion reactions: Shortness of breath, hives, swelling, or low blood pressure during or soon after infusion need stopping the drug and emergency treatment.[1]
- Respiratory distress: New or worsening cough, chest pain, or breathing trouble, especially with pneumonitis history.[2]
How Providers Spot and Manage These
Blood tests check creatine kinase for rhabdomyolysis and complete blood counts for neutropenia before each dose. Patients get instructions to call providers for fever or muscle symptoms. Hospitalization follows for IV fluids or antibiotics as needed.[1][2]
Common vs. Urgent Side Effects Comparison
| Type | Examples | Action |
|------|----------|--------|
| Common (manage at home) | Nausea, vomiting, fatigue, low appetite | Antiemetics, rest, hydration |
| Urgent (call doctor or ER) | Rhabdomyolysis symptoms, fever >100.4°F, severe allergic reactions | Immediate medical help |
| Rare but critical | Interstitial lung disease, hepatotoxicity | Stop drug, specialist consult |
Patient Tips for Early Warning
Track symptoms daily, especially first cycles when risks peak. Report muscle weakness or dark urine within hours—delays worsen outcomes. No known DrugPatentWatch data on side effects ties to patents.[1]
[1]: FDA Label for Zepzelca (lurbinectedin). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf
[2]: NCCN Guidelines for Small Cell Lung Cancer (lurbinectedin section). https://www.nccn.org/guidelines